Solitons in quadratic nonlinear photonic crystals.
We study solitons in one-dimensional quadratic nonlinear photonic crystals with modulation of both the linear and nonlinear susceptibilities. We derive averaged equations that include induced cubic nonlinearities, which can be defocusing, and we numerically find previously unknown soliton families. Because of these induced cubic terms, solitons still exist even when the effective quadratic nonlinearity vanishes and conventional theory predicts that there can be no soliton. We demonstrate that both bright and dark forms of these solitons can propagate stably.
Stable three-dimensional spinning optical solitons supported by competing quadratic and cubic nonlinearities.
We show that the quadratic interaction of fundamental and second harmonics in a bulk dispersive medium, combined with self-defocusing cubic nonlinearity, gives rise to completely localized spatiotemporal solitons (vortex tori) with vorticity s=1. There is no threshold necessary for the existence of these solitons. They are found to be stable if their energy exceeds a certain critical value, so that the stability domain occupies about 10% of the existence region of the solitons. On the contrary to spatial vortex solitons in the same model, the spatiotemporal ones with s=2 are never stable. These results might open the way for experimental observation of spinning three-dimensional solitons in optical media.
Antitumor activities of (2"R)-4'-O-tetrahydropyranyl-adriamycin (THP) and its combination with other antitumor agents on murine tumors.
(2''R)-4'-O-Tetrahydropyranyladriamycin (THP) is a new derivative of doxorubicin (adriamycin, ADM). The concentrations of THP and ADM required to inhibit by 50% the growth of a cultured L1210 cells was 0.003 microgram/ml and 0.016 microgram/ml, respectively. Various therapeutic designs of combinations of THP with other antitumor agents were investigated in vivo using the L1210 murine leukemia. The combination of THP with cytosine arabinoside (Ara-C), cyclocytidine hydrochloride (Cyclo-C), 6-mercaptopurine (6-MP) and cyclophosphamide (EX) showed a great effectiveness following daily intraperitoneal treatment from days 1 to 10. High therapeutic effects were also obtained with the combinations of THP with Ara-C, Cyclo-C, vincristine (VCR) and EX following intravenous combination therapy one day following implantation of L1210 leukemia. Schedule dependency and its therapeutic efficacy of THP were examined. THP showed almost the same antitumor activity on the solid-type sarcoma-180 or solid-type Ehrlich carcinoma as ADM by intraperitoneal or intravenous treatment. THP showed some superior activity to ADM in the advanced stage of L1210 leukemia. High antitumor activity of THP on murine leukemia L1210 has been reported by Tsuruo et al. (Cancer Res. 42: 1462-1467, 1982) and was also confirmed. THP gave many mice cures, especially in the intravenous treatment.